MUC1 and cancer: The aberrant glycosylation of MUC1 in both cancers and premalignant lesions makes it a valuable target, which was recognised in a National Cancer Institute (NCI) report from 2009 ranking MUC1 as one of the most promising peptides for cancer immunotherapy [17,18].